Drug intelligence / Profile preview

FG-3149

Development stage: Preclinical
Lead developer: FibroGen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

FG-3149 is a chimeric antibody that targets Connective Tissue Growth Factor (CTGF). It has shown activity in animal models of bronchopulmonary dysplasia, pressure overload-induced heart failure, genetic cardiomyopathy, and intestinal fibrosis associated with Crohn’s disease. Its mechanism involves inhibiting the fibrotic effects of CTGF, which plays a role in fibrosis and tissue repair.

Targets

CTGF (Connective tissue growth factor)

Beyond the preview

Go deeper on FG-3149.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FG-3149.

Explore the full profile